PMID- 18030649
OWN - NLM
STAT- MEDLINE
DCOM- 20080108
LR  - 20220409
IS  - 0176-3679 (Print)
IS  - 0176-3679 (Linking)
VI  - 40
IP  - 6
DP  - 2007 Nov
TI  - Switching to long-acting injectable risperidone is beneficial with regard to 
      clinical outcomes, regardless of previous conventional medication in patients 
      with schizophrenia.
PG  - 257-63
AB  - INTRODUCTION: Using an atypical long-acting antipsychotic may improve patient 
      outcome by offering the good efficacy and tolerability of an atypical 
      antipsychotic with improved compliance through depot administration. METHODS: 
      This subanalysis of an international, 6-month, open-label trial of risperidone 
      long-acting injectable (RLAI) focused on non-acute schizophrenic adult patients 
      switching from oral or depot conventional antipsychotic. Efficacy assessments 
      included Positive and Negative Syndrome Scale (PANSS), Global Assessment of 
      Functioning (GAF), quality of life, treatment satisfaction, hospitalization 
      rates, and treatment-emergent adverse events (TEAEs). RESULTS: Over 70% of 
      patients switching from oral (n=100) or depot (n=565) conventional medication 
      completed treatment. Improvements were observed for PANSS total and subscale 
      scores, GAF, quality of life, treatment satisfaction and hospitalization. Overall 
      RLAI was well tolerated. TEAEs occurring in >5% were: anxiety (11.0%), insomnia 
      (9.0%), weight increase (6.0%) for patients switching from oral, and weight 
      increase (6.0%) and disease exacerbation (5.3%) for patients switching from depot 
      medication. CONCLUSION: Patients with schizophrenia, unsatisfactorily treated 
      with oral or depot conventional antipsychotics, showed improvement in symptom 
      control, tolerability, and patient satisfaction after switching to RLAI.
FAU - Marinis, T De
AU  - Marinis TD
AD  - U.O. Salute Mentale ASL SA/2, Salerno, Italy.
FAU - Saleem, P T
AU  - Saleem PT
FAU - Glue, P
AU  - Glue P
FAU - Arnoldussen, W J
AU  - Arnoldussen WJ
FAU - Teijeiro, R
AU  - Teijeiro R
FAU - Lex, A
AU  - Lex A
FAU - Latif, M A
AU  - Latif MA
FAU - Medori, R
AU  - Medori R
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Pharmacopsychiatry
JT  - Pharmacopsychiatry
JID - 8402938
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Dyskinesia, Drug-Induced/epidemiology/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Psychiatric Status Rating Scales
MH  - Risperidone/administration & dosage/adverse effects/*therapeutic use
MH  - Schizophrenia/*drug therapy
MH  - Schizophrenic Psychology
MH  - Treatment Outcome
EDAT- 2007/11/22 09:00
MHDA- 2008/01/09 09:00
CRDT- 2007/11/22 09:00
PHST- 2007/11/22 09:00 [pubmed]
PHST- 2008/01/09 09:00 [medline]
PHST- 2007/11/22 09:00 [entrez]
AID - 10.1055/s-2007-992140 [doi]
PST - ppublish
SO  - Pharmacopsychiatry. 2007 Nov;40(6):257-63. doi: 10.1055/s-2007-992140.